SMPD1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL56262	0.59	6/20
Heptane (SCHEMBL5657)	0.52	6/20
Tiapamil (SCHEMBL93936)	0.48	6/20
Fantofarone (SCHEMBL77818)	0.45	6/20
SCHEMBL184249	0.66	5/20
SCHEMBL90417	0.64	5/20
SCHEMBL90498	0.58	5/20
SCHEMBL88815	0.57	5/20
SCHEMBL60424	0.52	5/20
SCHEMBL60846	0.52	5/20
SCHEMBL62052	0.52	5/20
SCHEMBL68346	0.48	5/20
SCHEMBL184987	0.71	4/20
SCHEMBL88998	0.60	4/20
SCHEMBL60987	0.54	4/20
SCHEMBL89015	0.52	4/20
SCHEMBL79175	0.51	4/20
SCHEMBL109694	0.51	4/20
SCHEMBL49451	0.50	4/20
SCHEMBL118383	0.50	4/20

Clinical trials — most relevant to SMPD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant	EARLY_PHASE1	COMPLETED
Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease	nan	NOT_YET_RECRUITING
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children	nan	NOT_YET_RECRUITING
High-Density Lipoprotein (HDL) Treatment Study	nan	COMPLETED
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency	nan	NOT_YET_RECRUITING
Biomarkers Of Lung InVolvement In ASMD	nan	UNKNOWN
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)	nan	APPROVED_FOR_MARKETING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)	nan	RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Diagnostic Creteria of Acid Sphingomyelinase Deficiency (ASMD)	nan	ACTIVE_NOT_RECRUITING
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Precision Medicine for Sng/Pain Control	nan	COMPLETED
A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)	nan	COMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders	nan	UNKNOWN
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease	nan	WITHDRAWN
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Magnetic Resonance Spectroscopy in Acid Sphingomyelinase Deficiency	nan	UNKNOWN
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SMPD1 binder may also engage these)

Protein	Name	Similarity
Q0VD19	—	0.997	Q0VD19 →
Q04519	—	0.996	Q04519 →
P58242	—	0.969	P58242 →
Q8BNJ2	—	0.969	Q8BNJ2 →
Q9TT93	—	0.968	Q9TT93 →
Q32M88	—	0.968	Q32M88 →
ADAMTS4	A disintegrin and metalloproteinase with thrombospondin motifs 4	0.967	landscape →
O09008	—	0.967	O09008 →
Q5RFQ8	—	0.966	Q5RFQ8 →
Q9EQV6	—	0.966	Q9EQV6 →
Q8HYJ3	—	0.966	Q8HYJ3 →
O35795	—	0.965	O35795 →
P56433	—	0.965	P56433 →
P53761	—	0.964	P53761 →
Q8HYJ5	—	0.964	Q8HYJ5 →
O89023	—	0.964	O89023 →
Q866F1	—	0.964	Q866F1 →
Q92485	—	0.964	Q92485 →
Q866C9	—	0.963	Q866C9 →
Q8HZR3	—	0.963	Q8HZR3 →
ENTPD2	Ectonucleoside triphosphate diphosphohydrolase 2	0.963	landscape →
Q11131	—	0.963	Q11131 →
Q9NPR2	—	0.963	Q9NPR2 →
FUT5	4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5	0.963	landscape →
Q62994	—	0.962	Q62994 →
P56434	—	0.962	P56434 →
Q13683	—	0.962	Q13683 →
Q8BP56	—	0.962	Q8BP56 →
Q712G6	—	0.962	Q712G6 →
Q866D9	—	0.962	Q866D9 →